Medical castration in the treatment of widespread cancers of the prostate. The role of buserelin

Medical castration with LHRH agonists is a significant trend in the treatment of locally advanced and metastatic prostate cancer (PC).The article is devoted to the effectiveness of synthetic LHRH agonist buserelin first due helmet (Buserelin-depo) in the treatment of patients with hormone dependent PC.Administration of Buserelin-depot results in a decrease of the prostate-specific antigen levels, stable reduction of serum testosterone to postcastration level, reduction in the size of the prostate chateau sissan 2019 and fewer voiding dysfunction symptoms without any serious side effects.